Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

PFE 35.04 -0.15 (-0.43%)
price chart
Pfizer sued by retailers for generic Lipitor delay
(Reuters) - Five big U.S. retailers filed an antitrust lawsuit against Pfizer Inc and India's Ranbaxy Laboratories Ltd on Thursday, accusing them of conspiring to delay sales of generic versions of Lipitor, the best-selling drug in history.
Pharmacies Sue Pfizer Over Lipitor  Wall Street Journal
Retailers sue Pfizer, charge generic Lipitor delay  Inquirer.net
Related articles »  
Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced an agreement with Pfizer for ...
Verastem Inks Separate Deals for Wnt and FAK Inhibitors  Genetic Engineering News
Related articles »  
Is Pfizer A Good Buy?
Pfizer has been involved in a series of acquisitions and sell offs, some cheered and some criticized by investors. They recently sold off their nutrition business to Nestle for $11.9 billion.
Pfizer Defends $25 Fair Value With Lyrica Patent Lawsuit Win  Trefis
Related articles »  
For Pfizer, Boston's medical labs a lure
Pfizer Inc., the world's largest pharmaceutical company, has a storied history of hunting for blockbuster drugs in its own labs.
Related articles »  
Why We Think Pfizer Remains Significantly Undervalued
If a company is undervalued both on a DCF and on a relative valuation basis and is showing improvement in technical and momentum indicators, it scores high on our scale.
Related articles »  
Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC ...
Pfizer-J&J Alzheimer's Drug Fails to Aid Cognition  Bloomberg
Hopes dim for Alzheimer's trials after Pfizer failure  Reuters
Related articles »  
Alnylam Pushes Forward In Amyloidosis After Pfizer Setback
Considering lack of progress in the RNAi space to date and the fact that the drug, ALN-TTR02, is one the company's biggest pipeline hopes, this makes encouraging news, particularly as a phase II study has already started.
Alnylam Gains on Treatment Data for Deadly Nerve Disease  Bloomberg
Related articles »  
Pfizer Wins Patent Ruling, Exclusive Sales for Lyrica Drug
July 20 (Bloomberg) -- Pfizer Inc., the world's largest drugmaker, convinced a U.S. judge that its patents for the pain-drug Lyrica are valid and infringed, giving it exclusive sales rights until 2018.
Pfizer Wins Lyrica Patent Ruling  Wall Street Journal
Related articles »  
Pfizer's Cost-Cuts Offset Loss of Lipitor
... helped cushion sales erosion from the loss of U.S. market exclusivity for blockbuster cholesterol-lowering drug Lipitor. The New York company's numbers were better than analysts expected, and Pfizer reiterated its forecast of full-year 2012 ...
Pfizer IPO, Cost Cuts Yield Time to Reinvent Its Research  Bloomberg
Pfizer Q2 Profit Up 25% Despite Stinging Loss Of Lipitor  Forbes
Related articles »  
Pfizer to return rights to three Acura products
(Reuters) - Pfizer Inc will return three products it was developing using Acura Pharmaceuticals Inc's abuse-resistant technology, Acura said on Friday.
Related articles »